Gambro breaks into Turkey through clinic purchase:
This article was originally published in Clinica
Swedish company Gambro has bought the Bulten dialysis centre, as well as a local sales company, in Turkey - its first move into this market, where it immediately takes a 10-12% share of the market for dialysis products. "The acquisition is a clear signal that we intend to move into this strategically important market, a market with more patients than Spain and almost as big as France," said Lennart la Fleur, managing director of Gambro Export. Over the past few years, the Turkish dialysis market has been growing at 15% annually.
You may also be interested in...
Health policy changes that President-elect Joe Biden will likely make during his four-year term include Medicaid expansion and a greater reliance on medical science, among others, experts say.
Already cleared to monitor the viral load in HIV-positive individuals, the test has now been approved for initial diagnosis as well.
As with its first two approved RNAi therapies, Alnylam will negotiate value-based agreements with payers, but for Oxlumo, approved in pediatric patients, it will offer a patient need adjustment.